# Four-year monitoring of the malaria vector Anopheles funestus in central-west Cameroon reveals an escalation of pyrethroid resistance combined with high malaria transmission

**Authors:** Hervé Raoul Tazokong, Magellan Tchouakui, Murielle Wondji, Onana Boyomo, Charles Sinclair Wondji

PMC · DOI: 10.1186/s12879-026-12708-w · 2026-01-28

## TL;DR

A four-year study in Cameroon shows increasing pyrethroid resistance in malaria mosquitoes, threatening control efforts and suggesting the need for new strategies.

## Contribution

The study reveals the rapid escalation of pyrethroid resistance in Anopheles funestus and identifies key genetic markers driving this resistance.

## Key findings

- Pyrethroid resistance in Anopheles funestus increased significantly from 2015 to 2023, with mortality rates dropping to as low as 8.5% for deltamethrin.
- Genetic markers G454A-CYP9K1 and 4.3 kb SV alleles were rapidly selected and reached high frequencies during the study period.
- PBO-based nets showed high efficacy, suggesting alternative resistance mechanisms beyond P450-based metabolic resistance.

## Abstract

Insecticide resistance presents a critical obstacle to malaria vector control, necessitating ongoing surveillance to guide control strategy. Despite widespread resistance in central Africa, the temporal adaptive changes driving resistance at both phenotypic and genetic levels remain uncharacterised. This study provides a comprehensive, four-year (2020–2023) assessment of Anopheles funestus s.s. in Mibellon, Cameroon, examining sporozoite infection rates and changes in insecticide resistance relative to 2015–2018 data.

Susceptibility profile, resistance intensity and cone assays were conducted following the WHO protocols. Sporozoite infection was detected in the mosquito head/thorax by TaqMan assay, confirmed by nested-PCR. Gene expression was assessed using RT-qPCR while insecticide resistance markers were genotyped using allele-specific PCR and LNA.

Plasmodium sporozoite infection rates ranged from 4 to 21% with the predominance of P. falciparum while P. malariae and P. ovale contributed often as mixed infections. ​Pyrethroid resistance significantly increased over time, with mortalities decreasing from 77.7% in 2015 to 23.2% in 2023 for permethrin and 46.6% in 2016 to just 8.5% in 2023 for deltamethrin, while full susceptibility was noted for organophosphates.​ Worryingly, high intensity of resistance was recorded for all pyrethroids. Partial recovery of susceptibility with PBO suggests other resistance mechanisms beside P450-based metabolic resistance. PBO-based nets yielded high efficacy which decreases slightly over time contrasting with complete loss in efficacy of pyrethroid-only nets. Monitoring the genetic markers revealed a rapid selection of G454A-CYP9K1 and 4.3 kb SV alleles, which increased considerably and reaching high frequency during the same period in which phenotypic resistance intensified. Other resistance markers (A296S-rdl and L119F-GSTe2) varied slightly in frequency while the N485I-Ace1, 6.5 kb SV, and CYP6P9a/b_R alleles were absent throughout the years. Consistent overexpression of CYP9K1 and CYP6P9a/b genes in pyrethroid-resistant mosquitoes highlights their potential role in resistance intensification.

The high infection rate and co-circulation of three Plasmodium species coupled with intense pyrethroid resistance pose a serious menace to malaria control in this region. To address these complex challenges, current vector control strategies should prioritize the deployment of PBO-based nets and organophosphates for IRS. Continuous vector and parasite surveillance should guide the choice of future interventions to accelerate progress towards malaria elimination

Not applicable

## Linked entities

- **Genes:** LOC1277432 (cytochrome P450 9e2) [NCBI Gene 1277432], LEO1 (LEO1 component of Paf1/RNA polymerase II complex) [NCBI Gene 123169], GstE2 (Glutathione S transferase E2) [NCBI Gene 37107], ACE (angiotensin I converting enzyme) [NCBI Gene 1636]
- **Chemicals:** permethrin (PubChem CID 40326), deltamethrin (PubChem CID 40585), PBO (PubChem CID 5794)
- **Diseases:** malaria (MONDO:0005136)
- **Species:** Anopheles funestus (taxon 62324), Plasmodium falciparum (taxon 5833), Plasmodium malariae (taxon 5858), Plasmodium ovale (taxon 36330)

## Full-text entities

- **Genes:** LEO1 (LEO1 component of Paf1/RNA polymerase II complex) [NCBI Gene 123169] {aka RDL}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}
- **Diseases:** malaria (MESH:D008288), Sporozoite infection (MESH:D007239)
- **Chemicals:** permethrin (MESH:D026023), organophosphates (MESH:D010755), Pyrethroid (MESH:D011722), PBO (-), deltamethrin (MESH:C017180)
- **Species:** Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833], Plasmodium malariae (species) [taxon 5858], Anopheles funestus (African malaria mosquito, species) [taxon 62324]
- **Mutations:** G454A, N485I, A296S, L119F

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12924244/full.md

---
Source: https://tomesphere.com/paper/PMC12924244